Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
COSCIENS Biopharma Inc. (CSCIF) had Income from Continuous Operations of $-10.36M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$7.50M |
|
$-10.36M |
|
$4.85M |
|
$2.65M |
|
$17.94M |
|
$-10.44M |
|
$0.09M |
|
$-10.35M |
|
$-10.11M |
|
$-10.36M |
|
|
Income from Continuous Operations |
$-10.36M |
$-10.36M |
|
$-10.12M |
|
$-10.44M |
|
$-9.37M |
|
3.17M |
|
3.17M |
|
$-3.27 |
|
$-3.27 |
|
| Balance Sheet Financials | |
$11.50M |
|
$9.81M |
|
$9.93M |
|
$21.43M |
|
$3.61M |
|
-- |
|
$13.98M |
|
$17.59M |
|
$3.84M |
|
$3.84M |
|
$3.84M |
|
3.18M |
|
| Cash Flow Statement Financials | |
$-8.47M |
|
$-0.46M |
|
$-0.41M |
|
$16.39M |
|
$7.31M |
|
$-9.09M |
|
$-0.01M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.18 |
|
-- |
|
-- |
|
-- |
|
-- |
|
35.30% |
|
-139.25% |
|
-139.25% |
|
-124.91% |
|
-138.01% |
|
-138.14% |
|
$-8.94M |
|
-- |
|
-- |
|
-- |
|
0.35 |
|
3.71 |
|
5.95 |
|
61.38 |
|
-269.60% |
|
-269.60% |
|
-48.33% |
|
-269.60% |
|
$1.21 |
|
$-2.82 |
|
$-2.68 |
|